Atlas Trials

A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

Clinical trial NCT01534052 · COMPLETED

Trial details

NCT number
NCT01534052
Sponsor
Astellas Pharma Inc
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Castration-Resistant Prostate Cancer (CRPC)
Start date
2011-10-21
Primary completion
2017-04-18
Enrollment
52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.